PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
11.35%
Some net income increase while GNPX is negative at -71.17%. John Neff would see a short-term edge over the struggling competitor.
1.31%
Less D&A growth vs. GNPX's 6.38%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-12.55%
Negative yoy SBC while GNPX is 239.37%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-199.74%
Negative yoy working capital usage while GNPX is 4047.53%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Lower AP growth vs. GNPX's 855.53%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-382.74%
Negative yoy usage while GNPX is 18467.74%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-25.35%
Negative yoy while GNPX is 855.53%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
2.31%
Operating cash flow growth below 50% of GNPX's 4.63%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
83.69%
Some CapEx rise while GNPX is negative at -160.68%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.69%
We have mild expansions while GNPX is negative at -6527.09%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
3875.79%
Issuance growth of 3875.79% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.